Luther Megan K, Mermel Leonard A, LaPlante Kerry L
Rhode Island Infectious Diseases Research Program, Providence Veterans Affairs Medical Center, Providence, RI, and Department of Pharmacy Practice, University of Rhode Island, Kingston, RI.
Department of Medicine, Warren Alpert Medical School of Brown University, Providence, RI, and Rhode Island Hospital, Division of Infectious Diseases, Providence, RI.
Am J Health Syst Pharm. 2016 Mar 1;73(5):315-21. doi: 10.2146/ajhp150029.
Results of a study of the activity of antibiotic lock solutions of vancomycin and telavancin against biofilm-forming strains of Staphylococcus epidermidis, Enterococcus faecalis, and Staphylococcus aureus are reported.
An established in vitro central venous catheter model was used to evaluate lock solutions containing vancomycin (5 mg/mL) or telavancin (5 mg/mL), with and without preservative-containing heparin sodium (with 0.45% benzyl alcohol) 2500 units/mL, heparin, and 0.9% sodium chloride solution. Lock solutions were introduced after 24-hour bacterial growth in catheters incubated at 35 °C. After 72 hours of exposure to the lock solutions, catheters were drained, flushed, and cut into segments for quantification of colony-forming units.
Against S. epidermidis, vancomycin and telavancin (with or without heparin) had similar activity. Against E. faecalis, vancomycin alone was more active than telavancin alone (p < 0.01). Against S. aureus, vancomycin plus heparin had activity similar to that of vancomycin alone; both lock agents had greater activity than telavancin (p < 0.02). The addition of heparin was associated with reduced activity of the vancomycin lock solution against S. epidermidis and E. faecalis (p < 0.01). Telavancin activity was not significantly changed with the addition of heparin.
In a central venous catheter model, vancomycin and telavancin activity was similar in reducing biofilm-producing S. epidermidis. However, vancomycin was more active than telavancin against E. faecalis and S. aureus. None of the tested agents eradicated biofilm-forming strains. The addition of preservative-containing heparin sodium 2500 units/mL to vancomycin was associated with reduced activity against S. epidermidis and E. faecalis.
报告一项关于万古霉素和特拉万星抗生素封管液对表皮葡萄球菌、粪肠球菌和金黄色葡萄球菌生物膜形成菌株活性的研究结果。
使用已建立的体外中心静脉导管模型,评估含万古霉素(5mg/mL)或特拉万星(5mg/mL)的封管液,添加或不添加含防腐剂的肝素钠(含0.45%苯甲醇)2500单位/mL、肝素和0.9%氯化钠溶液。在35℃孵育的导管中细菌生长24小时后引入封管液。暴露于封管液72小时后,排出导管内液体,冲洗导管,并将其切成段以定量菌落形成单位。
对于表皮葡萄球菌,万古霉素和特拉万星(添加或不添加肝素)具有相似的活性。对于粪肠球菌,单独使用万古霉素比单独使用特拉万星更具活性(p<0.01)。对于金黄色葡萄球菌,万古霉素加肝素的活性与单独使用万古霉素相似;两种封管剂的活性均高于特拉万星(p<0.02)。添加肝素与万古霉素封管液对表皮葡萄球菌和粪肠球菌的活性降低有关(p<0.01)。添加肝素后,特拉万星的活性没有显著变化。
在中心静脉导管模型中,万古霉素和特拉万星在减少生物膜产生的表皮葡萄球菌方面活性相似。然而,万古霉素对粪肠球菌和金黄色葡萄球菌的活性高于特拉万星。所测试的药物均未根除生物膜形成菌株。向万古霉素中添加含防腐剂的肝素钠2500单位/mL与对表皮葡萄球菌和粪肠球菌的活性降低有关。